Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
PBYI's Cash to Debt is ranked higher than
78% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 49.03 vs. PBYI: No Debt )
Ranked among companies with meaningful Cash to Debt only.
PBYI' s Cash to Debt Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Interest Coverage No Debt
PBYI's Interest Coverage is ranked higher than
70% of the 464 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PBYI: No Debt )
Ranked among companies with meaningful Interest Coverage only.
PBYI' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
F-Score: 3
Z-Score: 12.69
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROE (%) -127.60
PBYI's ROE (%) is ranked lower than
87% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. PBYI: -127.60 )
Ranked among companies with meaningful ROE (%) only.
PBYI' s ROE (%) Range Over the Past 10 Years
Min: -148.14  Med: -81.13 Max: -37.64
Current: -127.6
-148.14
-37.64
ROA (%) -109.13
PBYI's ROA (%) is ranked lower than
89% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: -26.97 vs. PBYI: -109.13 )
Ranked among companies with meaningful ROA (%) only.
PBYI' s ROA (%) Range Over the Past 10 Years
Min: -1700  Med: -106.29 Max: -36.94
Current: -109.13
-1700
-36.94
ROC (Joel Greenblatt) (%) -8719.79
PBYI's ROC (Joel Greenblatt) (%) is ranked lower than
85% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -366.92 vs. PBYI: -8719.79 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PBYI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -10585.02  Med: -6890.33 Max: -2978.59
Current: -8719.79
-10585.02
-2978.59
EBITDA Growth (3Y)(%) 29.70
PBYI's EBITDA Growth (3Y)(%) is ranked higher than
82% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -0.10 vs. PBYI: 29.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PBYI' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 29.7  Med: 539.9 Max: 882.4
Current: 29.7
29.7
882.4
EPS Growth (3Y)(%) 29.60
PBYI's EPS Growth (3Y)(%) is ranked higher than
83% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. PBYI: 29.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PBYI' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 53 Max: 883
Current: 29.6
0
883
» PBYI's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-09)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

PBYI Guru Trades in Q3 2015

Jim Simons 162,600 sh (New)
Steven Cohen 554,019 sh (+707.61%)
Jeremy Grantham 1,676,678 sh (+17.52%)
» More
Q4 2015

PBYI Guru Trades in Q4 2015

John Paulson 46,000 sh (New)
Jeremy Grantham 2,899,776 sh (+72.95%)
Steven Cohen 945,478 sh (+70.66%)
Jim Simons Sold Out
» More
Q1 2016

PBYI Guru Trades in Q1 2016

Samuel Isaly 142,000 sh (New)
John Paulson 70,300 sh (+52.83%)
Steven Cohen 1,157,700 sh (+22.45%)
Jeremy Grantham 2,010,801 sh (-30.66%)
» More
Q2 2016

PBYI Guru Trades in Q2 2016

John Paulson 145,800 sh (+107.40%)
Steven Cohen 1,415,800 sh (+22.29%)
Samuel Isaly 142,000 sh (unchged)
Jeremy Grantham Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with PBYI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:LXRX, NAS:DBVT, NYSE:AXON, NAS:ALDR, NAS:AGIO, NAS:ONCE, NAS:ITCI, NAS:OPHT, NAS:RLYP, NYSE:CBM, NAS:INVA, NAS:PRTA, OTCPK:SXMDF, NAS:NVAX, NAS:TBPH, NAS:CHRS, OTCPK:ABCZF, OTCPK:PFSCF, NAS:HALO, NAS:FPRX » details
Traded in other countries:0PB.Germany,
Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care.

Puma Biotechnology Inc was incorporated in Delaware on April 27, 2007. The Company is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care It is engaged in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The Company currently licenses the rights to three drug candidates: PB272 (neratinib (oral)), which are being developed for the treatment of breast cancer patients, non-small cell lung cancer and patients with HER2 mutation-positive solid tumors; PB272 (neratinib (intravenous)), which are being developed for the treatment of cancer patients; and PB357, which it believes can serve as a backup compound to PB272, and which are being evaluated for further development. The Company focused on developing neratinib for the treatment of patients with human epidermal growth factor receptor type 2, or HER2-positive, breast cancer, HER2 mutated non-small cell lung cancer, HER2-negative breast cancer that has a HER2 mutation and other solid tumors that have an activating mutation in HER2. Therapeutic strategies, such as the use of Herceptin (trastuzumab), Perjeta (pertuzumab), and Kadcyla (T-DM1), produced by Genentech, and Tykerb (lapatinib), produced by GlaxoSmithKline, given either alone or in combination with chemotherapy, have been developed to improve the treatment of this cancer by binding to the HER2 protein. The Company licenses the exclusive rights to its current drug candidates from Pfizer Inc., or Pfizer, which had previously been responsible for the clinical trials regarding neratinib. The Company's competitors include Genentech, GlaxoSmithKline, Roche, Boehringer Ingelheim, Takeda, Array Biopharma and Ambit Biosciences.

Ratios

vs
industry
vs
history
P/B 14.76
PBYI's P/B is ranked lower than
86% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. PBYI: 14.76 )
Ranked among companies with meaningful P/B only.
PBYI' s P/B Range Over the Past 10 Years
Min: 0  Med: 0 Max: 62.4
Current: 14.76
0
62.4
Current Ratio 3.95
PBYI's Current Ratio is ranked lower than
53% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.28 vs. PBYI: 3.95 )
Ranked among companies with meaningful Current Ratio only.
PBYI' s Current Ratio Range Over the Past 10 Years
Min: 0.67  Med: 5.6 Max: 91.42
Current: 3.95
0.67
91.42
Quick Ratio 3.95
PBYI's Quick Ratio is ranked lower than
51% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. PBYI: 3.95 )
Ranked among companies with meaningful Quick Ratio only.
PBYI' s Quick Ratio Range Over the Past 10 Years
Min: 0.67  Med: 5.6 Max: 91.42
Current: 3.95
0.67
91.42

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.20
PBYI's 3-Year Average Share Buyback Ratio is ranked higher than
73% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. PBYI: -4.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PBYI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -112.2  Med: -58 Max: -4.2
Current: -4.2
-112.2
-4.2

Valuation & Return

vs
industry
vs
history
Price/Net Cash 18.71
PBYI's Price/Net Cash is ranked lower than
78% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. PBYI: 18.71 )
Ranked among companies with meaningful Price/Net Cash only.
PBYI' s Price/Net Cash Range Over the Past 10 Years
Min: 4.69  Med: 14.69 Max: 60.47
Current: 18.71
4.69
60.47
Price/Net Current Asset Value 17.05
PBYI's Price/Net Current Asset Value is ranked lower than
78% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 5.50 vs. PBYI: 17.05 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
PBYI' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 4.26  Med: 13.42 Max: 55.83
Current: 17.05
4.26
55.83
Price/Tangible Book 14.74
PBYI's Price/Tangible Book is ranked lower than
81% of the 764 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. PBYI: 14.74 )
Ranked among companies with meaningful Price/Tangible Book only.
PBYI' s Price/Tangible Book Range Over the Past 10 Years
Min: 4.17  Med: 12.36 Max: 50.75
Current: 14.74
4.17
50.75
Earnings Yield (Greenblatt) (%) -15.03
PBYI's Earnings Yield (Greenblatt) (%) is ranked lower than
67% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. PBYI: -15.03 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PBYI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -48.52  Med: 0 Max: 0
Current: -15.03
-48.52
0

More Statistics

EPS (TTM) $ -8.01
Beta0.10
Short Percentage of Float30.19%
52-Week Range $19.74 - 107.49
Shares Outstanding (Mil)32.49

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 22 1,165
EPS ($) -8.45 11.84
EPS w/o NRI ($) -8.45 11.84
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NYSE:PBYI

Headlines

Articles On GuruFocus.com
Sam Isaly Purchases Stake in Puma Biotechnology May 03 2016 
Hall of Fame/ Hall of Shame: The Best and Worst Recommendations of 2014 Jan 09 2015 

More From Other Websites
Puma (PBYI) Neratinib's Application Validated in EU, Stock Up Aug 23 2016
PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events Aug 22 2016
After Medivation, These 6 Biotech Stocks Could Be M&A Targets Next Aug 22 2016
Puma Biotechnology Announces European Medicines Agency Validation of Marketing Authorization... Aug 22 2016
Puma Biotechnology Announces European Medicines Agency Validation of Marketing Authorization... Aug 22 2016
The Zacks Analyst Blog Highlights: Apple, Exact Sciences, Amkor Technology, Puma Biotechnology and... Aug 19 2016
4 Biggest Winners from This Earnings Season Aug 18 2016
PUMA BIOTECHNOLOGY, INC. Financials Aug 18 2016
Puma (PBYI) Posts Narrower Loss in Q2, Focus on Neratinib Aug 10 2016
Puma Biotech reports 2Q loss Aug 09 2016
Puma Biotech reports 2Q loss Aug 09 2016
PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 09 2016
Puma Biotechnology Reports Second Quarter 2016 Financial Results Aug 09 2016
Puma Biotechnology Reports Second Quarter 2016 Financial Results Aug 09 2016
PUMA BIOTECHNOLOGY, INC. Files SEC form 10-Q, Quarterly Report Aug 09 2016
What's in the Cards for Puma (PBYI) This Earnings Season? Aug 03 2016
Biotech Stock Mailbag: Puma Roars, Relypsa Soars, XBiotech Bombs Jul 29 2016
A Look At Puma Biotechnology Inc (PBYI)’s Breast Cancer Candidate Jul 25 2016
Is This the Turning Point Puma Biotech Investors Have Waited For? Jul 22 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)